In a recent interview CEOCFO Magazine spoke with Raymond Lai Chairman, President and CEO of Maple Leaf Green World (TSXV:MGW; OTCQB:MGWFF).
As quoted in the interview:

CEOCFO:Mr. Lai, Is Maple Leaf Green World on the growing side of medical marijuana, providing the marijuana for the product developers? What are you doing?
Mr. Lai: It is a pleasure to speak with you today. We started off as a greenhouse management company with operations in China for anti-desertification. We were helping the Chinese government to grow small trees so they can replant them in the semi desert area. We were doing that since 2006, but by 2013, the funding for these anti-desertification efforts were reduced by the government of China, and at the same time, the legalization of marijuana was happening in Canada. So we decided to change our focus from China back to Canada. We applied for the MMPR in 2014, which is the old licensing system, right now it is called ACMPR. While we were waiting, we also came across the opportunity to start another operation in California, which we believed it would be a good opportunity because California has more population than Canada, and they have a long time culture of marijuana usage. Therefore, we grabbed that opportunity and we started an operation in California at that time.
CEOCFO:Do you have the licensing in place for California in the United States?
Mr. Lai: It is a bit different in California. The state has approved medical marijuana and the licensing will be taking effect this year. But before that we had to operate as a joint venture partner with a non-profit co-operative. We supply them with capital and technology, and they grow marijuana for their members. Now the licensing scheme has come in for California, we will be able to grandfather it, and be able to apply for a license since we already have an operation in California. At present, we have 20 acres of land in Southern California, and we have two greenhouses operational – one for flowering , and one for propagation, and we have already produced two crops totaled about 300 lbs in 2016. The revenue will be about $300,000 and $400,000 US. Beside California, we have also purchased a cultivation license in Henderson, Nevada, very close to Las Vegas. The license we have there is for a 33,500 sq. feet indoor producing facility. In Nevada today, they have issued about 300 licenses, but only about 100 are operational. The rest of them are in remote areas where there is no water or electricity, so building the infrastructure alone would cost the licensees over million of dollars. Therefore, they will not become operational for a very long time. We on the other hand are one of the 100 that are operational now, and we have just also bought 4 acres of land in Henderson to build our own facility with special design to meet our requirement.
Going back to Canada, we had applied for the MMPR license since 2014, and finally got to the final Stage 5 in January 2016. Under the new ACMPR system, Stage 5 means that we can go ahead to renovate our existing facility to bring it up to the Health Canada standards, then Health Canada will send an inspector to do the inspection, and if everything meets their requirements then we will receive the license. There is a kind of guarantee in the regulations that they MUST give us the license if we meet their requirements. So these are our status in Canada, Nevada and California.
CEOCFO:Would you tell us about the markets in Canada and the US. How big are they?
Mr. Lai: In Canada, on the medical side right now we only have about 100,000 patients, but that is growing and could go up to about 2 or 300,000. That is still quite small, but recreationally it will be quite different once it kicks in, as they expect that over 10 million people will try it. So the market will be quite huge after the recreational kicks in. In California, it is much bigger, as there are currently over 1 million patients using marijuana for medical purpose. Recreationally, probably half of the California population is smoking marijuana. In Nevada, for medical use they only have about 30 to 40,000 patients now, but once recreational use kicks in, it will be huge as they allow the tourists to enjoy marijuana in Nevada, and each year there is over 30 or 40 million tourists going to Las Vegas.
CEOCFO:Do you have the funding to continue growth or are you looking for investors and partners?
Mr. Lai: We are in the process of raising CAD$ 5 million through non-brokered private placement now. Up to this point, all of our funding have been raised in this way. However, we are looking at institutional financing now too. I have been talking to three or four institutions that want to provide long-term or big financing for us, because they feel that our stock is undervalued and that we have much potential to grow.
CEOCFO:Address our readers in the business and investment community? Why should they be interested in Maple Leaf Green World?
Mr. Lai: First, I would like to emphasize that we are not just a Canadian MJ company. We are a North American MJ company with 3 projects located in strategic locations. In B.C. we are close to Vancouver, as a sea port, it allows us to easily export our products overseas, especially to Asia, an area untouched with MJ. Then in California, the biggest populated state in the US, and they have a long history of using marijuana. Then in Nevada, especially in Las Vega, it is one of the biggest tourist entertainment centers in the world. Therefore, we have 3 good locations for our projects. Secondly, our stock price is currently quite low comparing to other MJ stocks, and our outstanding shares is also quite low, just 120 million shares outstanding and only 60 million are floating. Therefore, the opportunity for our price to go up is higher than other MJ companies. Thirdly, our long term goal is to produce Cannabis oil, and we have an Cannabis oil project already in the making. Our long term goal is to export the Cannabis oil overseas. All these 3 points have made us distinctive from other MJ companies.


Connect with Maple Leaf Green World (TSXV:MGW; OTCQB:MGWFF) to receive an Investor Presentation.

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less